Edition:
United States

Edwards Lifesciences Corp (EW)

EW on New York Consolidated

90.37USD
9 Dec 2016
Change (% chg)

$1.07 (+1.20%)
Prev Close
$89.30
Open
$89.53
Day's High
$92.98
Day's Low
$89.30
Volume
4,172,582
Avg. Vol
1,926,517
52-wk High
$121.75
52-wk Low
$72.20

EW

Chart for EW

About

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a... (more)

Overall

Beta: 0.63
Market Cap(Mil.): $19,322.37
Shares Outstanding(Mil.): 213.81
Dividend: --
Yield (%): --

Financials

  EW Industry Sector
P/E (TTM): 35.74 56.44 30.36
EPS (TTM): 2.53 -- --
ROI: 15.43 7.06 15.27
ROE: 21.58 10.66 16.60

Edwards Lifesciences to buy Israel's Valtech for up to $690 million

JERUSALEM Edwards Lifesciences Corp on Monday said it has agreed to buy Israel's Valtech Cardio for $340 million in stock and cash, with the potential for an additional $350 million in pre-specified milestone-driven payments over the next 10 years.

Nov 28 2016

UPDATE 1-Edwards Lifesciences to buy Israel's Valtech for up to $690 mln

JERUSALEM, Nov 28 Edwards Lifesciences Corp on Monday said it has agreed to buy Israel's Valtech Cardio for $340 million in stock and cash, with the potential for an additional $350 million in pre-specified milestone-driven payments over the next 10 years.

Nov 28 2016

Edwards Lifesciences to buy Israel's Valtech for up to $690 mln

JERUSALEM, Nov 28 Edwards Lifesciences Corp on Monday said it has agreed to buy Israel's Valtech Cardio for $340 million in stock and cash, with the potential for an additional $350 million in pre-specified milestone-driven payments over the next 10 years.

Nov 28 2016

BRIEF-Edwards enters into agreement to acquire Valtech Cardio

* Purchase price of Valtech is $340 million in stock and cash at closing,

Nov 28 2016

Edwards wins $21 mln in enhanced damages in heart valve trade secrets case

A federal judge in Boston has ordered medical device maker Neovasc Inc to pay an extra $21 million in enhanced damages on top of a $70 million jury verdict in a trade secret lawsuit filed by a former client.

Oct 31 2016

Earnings in focus as Apple weighs; Boeing lifts Dow

Quarterly results were the main driver for Wall Street on Wednesday as a decline in Apple shares weighed on the S&P 500 and Nasdaq, while the price-weighted Dow Industrials was buoyed by gains in Boeing. | Video

Oct 26 2016

Edwards Lifesciences third quarter sales disappoint, shares slide

Edwards Lifesciences Corp on Tuesday reported third quarter sales of its minimally invasive heart valve replacements that fell short of Wall Street estimates, and its previously high-flying shares plunged more than 14 percent.

Oct 25 2016

UPDATE 2-Edwards Lifesciences 3rd-qtr sales disappoint, shares slide

Oct 25 Edwards Lifesciences Corp on Tuesday reported third quarter sales of its minimally invasive heart valve replacements that fell short of Wall Street estimates, and its previously high-flying shares plunged more than 14 percent.

Oct 25 2016

Edwards Lifesciences boosts outlook after profit meets Street view

Oct 25 Edwards Lifesciences Corp on Tuesday reported higher third quarter profit in line with Wall Street estimates on increased sales of its minimally invasive heart valve replacement, and the company raised its full-year earnings forecast.

Oct 25 2016

FDA widens use of Edwards' devices for heart valve replacement

The U.S. Food and Drug Administration has widened the use of Edwards Lifesciences Corp's heart valves to patients at intermediate risk of complications if they underwent open heart surgery.

Aug 18 2016

Earnings vs. Estimates